Nabriva Therapeutics to Present Data at IDWeek 2021

Nabriva Therapeutics

FORT WASHINGTON, PA — Nabriva Therapeutics plc (NASDAQ: NBRV) announced data presentation at the Infectious Disease Society of America (IDSA) IDWeek™ 2021, taking place virtually from September 29 – October 3, 2021.

Nabriva, along with its collaborators, will exhibit a poster presentation on the in vitro activity of lefamulin against Staphylococcus aureus isolated from the lower respiratory tract of children with cystic fibrosis. XENLETA® (lefamulin) is a first-in-class pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia (CABP).

PRESENTATION:

Session Title: Respiratory Infections – Bacterial
Poster Title: “In Vitro Activity of Lefamulin against Staphylococcus aureus isolated from the Lower Respiratory Tract of Children with Cystic Fibrosis”
Session ID: 1058520
Presenting Author: Dr. Helio S. Sader, M.D., Ph.D., FIDSA (Sr. Director, JMI Laboratories)

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.